Stockscreener 앱 받기
1.41
2.17%
0.03
시간 외 거래:
1.41
Renovorx Inc 주식(RNXT)의 최신 뉴스
Short Interest in RenovoRx, Inc. (NASDAQ:RNXT) Declines By 35.4% - Defense World
Citadel Advisors LLC Invests $49,000 in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World
RenovoRX chief medical officer buys $29,399 in common stock By Investing.com - Investing.com Canada
RenovoRX chief medical officer buys $29,399 in common stock - Investing.com Australia
Insider Buying: Ramtin Agah Acquires Additional Shares of RenovoRx Inc (RNXT) - GuruFocus
RenovoRx (NASDAQ:RNXT) Stock Rating Upgraded by Wall Street Zen - Defense World
RenovoRx (NASDAQ:RNXT) Given New $11.50 Price Target at Ascendiant Capital Markets - Defense World
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results - Yahoo Finance
Ascendiant Capital raises RenovoRx stock price target to $11.50 By Investing.com - Investing.com Canada
RenovoRx (RNXT) Price Target Increased by Ascendiant Analyst | R - GuruFocus
RenovoRx (RNXT) Price Target Increased by Ascendiant Analyst | RNXT Stock News - GuruFocus
RenovoRx (RNXT) Price Target Raised to $11.50 by Ascendiant Capi - GuruFocus
Ascendiant Capital raises RenovoRx stock price target to $11.50 - Investing.com
New U.S. Patent Issued to RenovoRx for Drug Therapy Platform - Medical Product Outsourcing
RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment - simplywall.st
Q2 Earnings Forecast for RenovoRx Issued By HC Wainwright - Defense World
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates - MSN
RenovoRx (NASDAQ:RNXT) Receives “Buy” Rating from HC Wainwright - Defense World
RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook - TipRanks
RenovoRx (RNXT): HC Wainwright Reiterates Buy Rating with $3.00 Target | RNXT Stock News - GuruFocus
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript - MSN
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating - TipRanks
RenovoRx Earnings Call: Positive Outlook Amid Growth - TipRanks
RenovoRx Inc (RNXT) Q1 2025 Earnings: EPS of -$0.08 Beats Estima - GuruFocus
RenovoRx earnings beat, revenue fell short of estimates - Investing.com Australia
Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations By Investing.com - Investing.com Nigeria
RenovoRx Reports Promising Q1 2025 Financial Results - TipRanks
Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations - Investing.com
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com India
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace
RenovoRx Q1 2025 Earnings Call Transcript - MarketBeat
RenovoRx reports Q1 EPS (8c), consensus (8c) - TipRanks
RenovoRx (RNXT) Reports Strong Q1 Revenue Surpassing Expectations | RNXT Stock News - GuruFocus
RenovoRx Reports Strong Q1 2025 Financial Results - TipRanks
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - BioSpace
RenovoRx Expands RenovoCath Production to Meet an Increasing Demand - Zenopa
Renaissance Technologies LLC Makes New Investment in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World
RenovoRx Ramps Up U.S. Production of RenovoCath Devices - Medical Product Outsourcing
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform - Business Wire
RenovoRx (RNXT) Projected to Post Earnings on Friday - Defense World
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET - BioSpace
CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer - Curetoday
Ascendiant Capital Markets Forecasts Strong Price Appreciation for RenovoRx (NASDAQ:RNXT) Stock - The AM Reporter
RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer T - GuruFocus
RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer Treatment | RNXT Stock News - GuruFocus
Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx'S Ongoing Phase III Tiger-Pac Clinical Trial - marketscreener.com
2.27%
1.55%
자본화:
|
볼륨(24시간):